|
|
|
|
|
|
|
We enjoyed visiting with so many of you at the NARFE convention in Reno. Thank you for making us feel welcome at your event! And thank you to all NARFE members for everything that you do to advance our mission. Together, we continue to build our legacy toward our greatest hope: a world without Alzheimer's disease. We hope you enjoy and share this month's update.
|
|
|
|
|
Start your Walk to End Alzheimer's team today and be entered to win a Walk hoodie!
As you know, NARFE now is an official National Team for the Walk to End Alzheimer's®. Our goal is to raise $50,000 across all NARFE regions. As a NARFE member, you can help by encouraging your friends and family to join your team! And when you register your NARFE team by Sept. 23 with a minimum of $25 raised, you'll be entered in a raffle to win your very own Walk hoodie!
|
|
|
As a brand-new incentive, all teams registered by Sept. 23 who raise a minimum of $25 will be entered in a raffle to earn a Walk hoodie!
|
|
Many teams will Walk, and all will contribute to our legacy, but only the top NARFE fundraising team will earn the coveted NARFE Walk to End Alzheimer's Traveling Trophy! Will it be yours?
Register today!
|
|
Five simple steps to register:
- Visit alz.org/narfewalks.
- Click on "Start a team."
- Find the closest Walk to you by typing in your zip code.
- Enter your NARFE chapter name in your team name.
- Complete the online registration form to gain access to your Participant Center, where you can gain access to great fundraising and team recruitment tools!
|
|
|
|
|
Experimental Alzheimer's drug shows promise against brain plaques
An experimental drug called aducanumab dramatically reduced the toxic plaques found in the brains of people living with Alzheimer's disease, according to results of a Phase1b clinical trial designed to test safety and tolerability rather than effectiveness. The results, previously reported at the Alzheimer's Association International Conference® 2015 (AAIC®), hinted that the drug may also be able to slow the loss of memory and thinking. Experts caution that additional, larger studies will be necessary to determine if aducanumab has an effect on slowing down Alzheimer's. Learn more.
|
|
|
|
|
Second Alzheimer's professional judgment budget reflects urgent need to find a cure or treatment
The National Institutes of Health (NIH) on Aug. 1 recommended in its second-ever professional judgment budget for Alzheimer's research a $414 million increase for FY2018 annual spending "to meet one of the greatest challenges of our time — the development of effective treatments for and prevention of Alzheimer's and related dementias by 2025." The professional judgment budget reflects the current state of Alzheimer's knowledge and "outlines the toll Alzheimer's takes on our nation and the scientific opportunities we could pursue with enhanced funding," NIH said in releasing the budget. The funding would support effectively deployable research identified by leading scientists to meet the 2025 prevention and treatment goal established by the National Plan to Address Alzheimer's Disease.
Learn more.
|
|
|
|
|
Join Our Mailing List
|
|
|
|
|
NARFE Contributions to Advance Alzheimer's Research
Your donation goes directly to support research through the NARFE Alzheimer's Fund.
Help us reach our NEW goal of $12 million!
|
|
|
|
24/7 Helpline: 1-800-272-3900
|
|
